

Palash Sanphui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1367086/publications.pdf>

Version: 2024-02-01

35
papers

2,922
citations

279798

23
h-index

361022

35
g-index

35
all docs

35
docs citations

35
times ranked

2898
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymorphs, Salts, and Cocrystals: Whatâ€™s in a Name?. <i>Crystal Growth and Design</i> , 2012, 12, 2147-2152.	3.0	767
2	New polymorphs of curcumin. <i>Chemical Communications</i> , 2011, 47, 5013.	4.1	242
3	Cocrystals of Hydrochlorothiazide: Solubility and Diffusion/Permeability Enhancements through Drugâ€™Coformer Interactions. <i>Molecular Pharmaceutics</i> , 2015, 12, 1615-1622.	4.6	218
4	Fast Dissolving Curcumin Cocrystals. <i>Crystal Growth and Design</i> , 2011, 11, 4135-4145.	3.0	189
5	Salt and Cocrystals of Sildenafil with Dicarboxylic Acids: Solubility and Pharmacokinetic Advantage of the Glutarate Salt. <i>Molecular Pharmaceutics</i> , 2013, 10, 4687-4697.	4.6	131
6	Crystal Engineering of Stable Temozolomide Cocrystals. <i>Chemistry - an Asian Journal</i> , 2012, 7, 2274-2285.	3.3	124
7	Fast dissolving eutectic compositions of curcumin. <i>International Journal of Pharmaceutics</i> , 2012, 439, 63-72.	5.2	110
8	Tuning Mechanical Properties of Pharmaceutical Crystals with Multicomponent Crystals: Voriconazole as a Case Study. <i>Molecular Pharmaceutics</i> , 2015, 12, 889-897.	4.6	107
9	Obtaining Synthron Modularity in Ternary Cocrystals with Hydrogen Bonds and Halogen Bonds. <i>Crystal Growth and Design</i> , 2014, 14, 5293-5302.	3.0	102
10	Pharmaceutical Cocrystals of Niclosamide. <i>Crystal Growth and Design</i> , 2012, 12, 4588-4599.	3.0	93
11	Solubility Advantage of Tenoxicam Phenolic Cocrystals Compared to Salts. <i>Crystal Growth and Design</i> , 2013, 13, 1988-2003.	3.0	82
12	Solubility-Hardness Correlation in Molecular Crystals: Curcumin and Sulfathiazole Polymorphs. <i>Crystal Growth and Design</i> , 2014, 14, 3054-3061.	3.0	79
13	Acemetacin polymorphs: a rare case of carboxylic acid catemer and dimer synthons. <i>CrystEngComm</i> , 2013, 15, 34-38.	2.6	67
14	New Solid Forms of the Anti-HIV Drug Etravirine: Salts, Cocrystals, and Solubility. <i>Crystal Growth and Design</i> , 2013, 13, 3681-3690.	3.0	67
15	Polymorphism in Isomeric Dihydroxybenzoic Acids. <i>Crystal Growth and Design</i> , 2010, 10, 2388-2399.	3.0	61
16	High Solubility Piperazine Salts of the Nonsteroidal Anti-Inflammatory Drug (NSAID) Meclofenamic Acid. <i>Crystal Growth and Design</i> , 2012, 12, 2023-2036.	3.0	55
17	Curcumin, a Biological Wonder Molecule: A Crystal Engineering Point of View. <i>Crystal Growth and Design</i> , 2018, 18, 5690-5711.	3.0	54
18	Acemetacin cocrystals and salts: structure solution from powder X-ray data and form selection of the piperazine salt. <i>IUCr</i> , 2014, 1, 136-150.	2.2	50

#	ARTICLE	IF	CITATIONS
19	Temozolomide Cocrystals with Carboxamide Coformers. <i>Crystal Growth and Design</i> , 2013, 13, 2208-2219.	3.0	46
20	Tuning solubility and stability of hydrochlorothiazide co-crystals. <i>Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials</i> , 2014, 70, 81-90.	1.1	44
21	Polymorphism in Secondary Benzene Sulfonamides. <i>Crystal Growth and Design</i> , 2010, 10, 4550-4564.	3.0	39
22	Phase Transformation in Conformational Polymorphs of Nimesulide. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2287-2299.	3.3	38
23	Polymorphs and Cocrystals of Nalidixic Acid. <i>Crystal Growth and Design</i> , 2012, 12, 4963-4971.	3.0	25
24	New multi-component solid forms of anti-cancer drug Erlotinib: role of auxiliary interactions in determining a preferred conformation. <i>Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials</i> , 2016, 72, 291-300.	1.1	21
25	Correction for Polymorphs, Salts and Cocrystals: Whatâ€™s in a Name?. <i>Crystal Growth and Design</i> , 2012, 12, 4290-4291.	3.0	17
26	Temozolomide hydrochloride dihydrate. <i>CrystEngComm</i> , 2013, 15, 666-671.	2.6	17
27	Salts and Co-crystals of Theobromine and their phase transformations in water. <i>Journal of Chemical Sciences</i> , 2014, 126, 1249-1264.	1.5	17
28	Intriguing High κ^3 Cocrystals of Emtricitabine. <i>Crystal Growth and Design</i> , 2020, 20, 4886-4891.	3.0	12
29	Tuning Diffusion Permeability of an Anti-Retroviral Drug, Emtricitabine, via Multicomponent Crystallizations. <i>Crystal Growth and Design</i> , 2021, 21, 1548-1561.	3.0	12
30	Lower melting pharmaceutical cocrystals of metaxalone with carboxamide functionalities. <i>Journal of Molecular Structure</i> , 2019, 1178, 479-490.	3.6	9
31	Multicomponent solid forms of the uric acid reabsorption inhibitor lesinurad and cocrystal polymorphs with urea: DFT simulation and solubility study. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2019, 75, 1102-1117.	0.5	8
32	Effect of Substituents on Molecular Geometry and Self-Aggregation in the Crystal Structures of Ethylenediamine- κ^3 - κ^4 -tetraamides. <i>Crystal Growth and Design</i> , 2007, 7, 1872-1880.	3.0	7
33	Isostructural cocrystals of metaxalone with improved dissolution characteristics. <i>RSC Advances</i> , 2021, 11, 30689-30700.	3.6	6
34	Organic molecular salts of allopurinol with improved solubility. <i>Materials Today: Proceedings</i> , 2021, 40, S210-S215.	1.8	4
35	A disappearing metastable hydrate form of L-citrulline: Variable conformations in polymorphs and hydrates. <i>Journal of Molecular Structure</i> , 2020, 1201, 127179.	3.6	2